Biocytogen-B (02315) has announced its financial results for the six months ended June 30, 2026, reporting revenue of RMB 941 million, a year-on-year increase of 51.6%. The company's profit attributable to equity shareholders reached RMB 241 million, marking a remarkable 402.3% surge compared to the same period last year. Basic earnings per share stood at RMB 0.54 for the period.
The revenue growth during the period was primarily driven by increased sales of model animals, preclinical pharmacology and efficacy evaluations, as well as antibody development services. Following years of strategic positioning, the company has established a "dual-engine" business ecosystem encompassing preclinical products and services alongside antibody discovery. These two segments empower each other through technological synergy and resource integration, consistently unlocking growth potential.
The company remains steadfast in its research-driven approach, continuously delivering high-quality, globally competitive R&D products and services to biopharmaceutical enterprises both domestically and internationally. Leveraging the expansion of diversified drug formats such as bispecific antibodies, multispecific antibodies, and nucleic acid-based therapeutics, the company's first-mover advantage in innovative animal models has become increasingly prominent. Sales of its industry-leading bispecific and multispecific antibody animal models, characterized by high R&D barriers and premium pricing, are exhibiting rapid growth trends.
During the first half of 2026, the preclinical products and services segment, centered on innovative animal model sales, generated operating revenue of RMB 723.5 million, representing a 57.9% increase from the same period last year, while maintaining a robust gross margin above 70%. Within this segment, innovative animal model sales alone contributed RMB 445.8 million in operating revenue, up 62.4% year-on-year with a gross margin of approximately 82.3%. Backed by its globally leading competitive advantages, this business has sustained high growth momentum over the long term. In response to rising global demand, the company is actively advancing capacity expansion to further consolidate and broaden its worldwide leadership position.
In May 2026, the company officially launched RenSuper Workstation™, a next-generation AI-driven antibody discovery platform. Empowered by AI and automated smart manufacturing platforms, the antibody discovery business achieved operating revenue of RMB 217.9 million in the first half of 2026, a 33.8% increase year-on-year, with gross margin reaching approximately 92.8%. As of June 30, 2026, the company had cumulatively signed approximately 455 collaborative development, licensing, or transfer agreements for therapeutic antibodies and various clinical assets. It has also established RenMice platform licensing and development partnerships with collaborators including multiple multinational pharmaceutical companies. Notably, over 105 new agreements were signed during the first half of 2026, representing a year-on-year growth of approximately 31.3%.
Looking ahead, the company plans to leverage AI and automated platforms to further elevate antibody R&D toward more efficient and intelligent innovation.
Comments